Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month

Posted on by wpadmin
Headquarters of US Food and Drug Administration (FDA)

Grandbrothers

  • The FDA’s Oncologic Drugs Advisory Committee will meet on May 20 and 21 to discuss supplemental New Drug Applications from Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and Roche’s (OTCQX:RHHBY) Genentech unit.
  • The panel will discuss Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for

Leave a Reply

Your email address will not be published. Required fields are marked *